Fleseriu M, Langlois F, Lim DST et al (2022) Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol 10:804–826. https://doi.org/10.1016/S2213-8587(22)00244-3

Article  CAS  PubMed  Google Scholar 

Giustina A, Barkan A, Beckers A et al (2020) A consensus on the diagnosis and treatment of acromegaly comorbidities: an update. J Clin Endocrinol Metab 105:e937–e946. https://doi.org/10.1210/clinem/dgz096

Article  Google Scholar 

Melmed S, Bronstein MD, Chanson P et al (2018) A consensus statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol 14:552–561. https://doi.org/10.1038/s41574-018-0058-5

Article  PubMed  PubMed Central  Google Scholar 

Cuevas-Ramos D, Carmichael JD, Cooper O et al (2015) A structural and functional acromegaly classification. J Clin Endocrinol Metab 100:122–131. https://doi.org/10.1210/jc.2014-2468

Article  CAS  PubMed  Google Scholar 

Carmichael JD, Bonert VS, Nuño M et al (2014) Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. J Clin Endocrinol Metab 99:1825–1833. https://doi.org/10.1210/jc.2013-3757

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gadelha MR, Kasuki L, Korbonits M (2013) Novel pathway for somatostatin analogs in patients with acromegaly. Trends Endocrinol Metab 24:238–246. https://doi.org/10.1016/j.tem.2012.11.007

Article  CAS  PubMed  Google Scholar 

Fleseriu M, Biller BMK, Freda PU et al (2021) A Pituitary Society update to acromegaly management guidelines. Pituitary 24:1–13. https://doi.org/10.1007/s11102-020-01091-7

Article  PubMed  Google Scholar 

Ilie M-D, Tabarin A, Vasiljevic A et al (2022) Predictive factors of somatostatin receptor ligand response in acromegaly—a prospective study. J Clin Endocrinol Metab 107:2982–2991. https://doi.org/10.1210/clinem/dgac512

Article  PubMed  Google Scholar 

Lamberts SW, Uitterlinden P, Schuijff PC, Klijn JG (1988) Therapy of acromegaly with sandostatin: the predictive value of an acute test, the value of serum somatomedin-C measurements in dose adjustment and the definition of a biochemical “cure.” Clin Endocrinol 29:411–420. https://doi.org/10.1111/j.1365-2265.1988.tb02890.x

Article  CAS  Google Scholar 

Puig Domingo M (2015) Treatment of acromegaly in the era of personalized and predictive medicine. Clin Endocrinol 83:3–14. https://doi.org/10.1111/cen.12731

Article  CAS  Google Scholar 

Gadelha MR, Wildemberg LE, Kasuki L (2022) The future of somatostatin receptor ligands in acromegaly. J Clin Endocrinol Metab 107:297–308. https://doi.org/10.1210/clinem/dgab726

Article  PubMed  Google Scholar 

Gilbert JA, Miell JP, Chambers SM et al (2005) The nadir growth hormone after an octreotide test dose predicts the long-term efficacy of somatostatin analogue therapy in acromegaly. Clin Endocrinol 62:742–747. https://doi.org/10.1111/j.1365-2265.2005.02278.x

Article  CAS  Google Scholar 

Halperin I, Nicolau J, Casamitjana R et al (2008) A short acute octreotide test for response prediction of long-term treatment with somatostatin analogues in acromegalic patients. Horm Metab Res 40:422–426. https://doi.org/10.1055/s-2008-1065339

Article  CAS  PubMed  Google Scholar 

Taboada GF, Donangelo I, Guimarães RFC et al (2005) Acute test with subcutaneous octreotide as a predictor of the response to treatment with octreotide LAR. Arq Bras Endocrinol Metabol 49:390–395. https://doi.org/10.1590/s0004-27302005000300010

Article  PubMed  Google Scholar 

de Herder WW, Taal HR, Uitterlinden P et al (2005) Limited predictive value of an acute test with subcutaneous octreotide for long-term IGF-I normalization with Sandostatin LAR in acromegaly. Eur J Endocrinol 153:67–71. https://doi.org/10.1530/eje.1.01935

Article  CAS  PubMed  Google Scholar 

Colao A, Pivonello R, Auriemma RS et al (2008) Growth hormone-secreting tumor shrinkage after 3 months of octreotide-long-acting release therapy predicts the response at 12 months. J Clin Endocrinol Metab 93:3436–3442. https://doi.org/10.1210/jc.2008-0424

Article  PubMed  Google Scholar 

Colao A, Auriemma RS, Lombardi G, Pivonello R (2011) Resistance to somatostatin analogs in acromegaly. Endocr Rev 32:247–271. https://doi.org/10.1210/er.2010-0002

Article  CAS  PubMed  Google Scholar 

Petersenn S, Houchard A, Sert C et al (2020) Predictive factors for responses to primary medical treatment with lanreotide autogel 120 mg in acromegaly: post hoc analyses from the PRIMARYS study. Pituitary 23:171–181. https://doi.org/10.1007/s11102-019-01020-3

Article  CAS  PubMed  Google Scholar 

Giustina A, di Filippo L, Uygur MM, Frara S (2023) Modern approach to resistant acromegaly. Endocrine 80:303–307. https://doi.org/10.1007/s12020-023-03317-7

Article  CAS  PubMed  Google Scholar 

Katznelson L, Laws ER Jr, Melmed S et al (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99:3933–3951. https://doi.org/10.1210/jc.2014-2700

Article  CAS  PubMed  Google Scholar 

Heck A, Ringstad G, Fougner SL et al (2012) Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly. Clin Endocrinol 77:72–78. https://doi.org/10.1111/j.1365-2265.2011.04286.x

Article  CAS  Google Scholar 

Hagiwara A, Inoue Y, Wakasa K et al (2003) Comparison of growth hormone-producing and non-growth hormone-producing pituitary adenomas: imaging characteristics and pathologic correlation. Radiology 228:533–538. https://doi.org/10.1148/radiol.2282020695

Article  PubMed  Google Scholar 

Isojima T, Shimatsu A, Yokoya S et al (2012) Standardized centile curves and reference intervals of serum insulin-like growth factor-I (IGF-I) levels in a normal Japanese population using the LMS method. Endocr J 59:771–780. https://doi.org/10.1507/endocrj.ej12-0110

Article  CAS  PubMed  Google Scholar 

Colao A, Ferone D, Lastoria S et al (1996) Prediction of efficacy of octreotide therapy in patients with acromegaly. J Clin Endocrinol Metab 81:2356–2362. https://doi.org/10.1210/jcem.81.6.8964877

Article  CAS  PubMed  Google Scholar 

Yamamoto M, Fukuoka H, Iguchi G et al (2015) The prevalence and associated factors of colorectal neoplasms in acromegaly: a single center based study. Pituitary 18:343–351. https://doi.org/10.1007/s11102-014-0580-y

Article  PubMed  Google Scholar 

Coopmans EC, Korevaar TIM, van Meyel SWF et al (2020) Multivariable prediction model for biochemical response to first-generation somatostatin receptor ligands in acromegaly. J Clin Endocrinol Metab 105:2964–2974. https://doi.org/10.1210/clinem/dgaa387

Article  Google Scholar 

Giustina A, Mazziotti G, Torri V et al (2012) Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS ONE 7:e36411. https://doi.org/10.1371/journal.pone.0036411

Article  CAS  PubMed  PubMed Central  Google Scholar 

Casar-Borota O, Heck A, Schulz S et al (2013) Expression of SSTR2a, but not of SSTRs 1, 3, or 5 in somatotroph adenomas assessed by monoclonal antibodies was reduced by octreotide and correlated with the acute and long-term effects of octreotide. J Clin Endocrinol Metab 98:E1730–E1739. https://doi.org/10.1210/jc.2013-2145

Article  CAS  PubMed  Google Scholar 

Wang M, Shen M, He W et al (2016) The value of an acute octreotide suppression test in predicting short-term efficacy of somatostatin analogues in acromegaly. Endocr J 63:819–834. https://doi.org/10.1507/endocrj.EJ16-0175

Article  CAS  PubMed  Google Scholar 

Karavitaki N, Botusan I, Radian S et al (2005) The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly. Clin Endocrinol 62:282–288. https://doi.org/10.1111/j.1365-2265.2004.02191.x

Article  CAS  Google Scholar 

Bianchi A, Valentini F, Iuorio R et al (2013) Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes. J Exp Clin Cancer Res 32:40. https://doi.org/10.1186/1756-9966-32-40

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chiloiro S, Costa D, Lauretta R et al (2022) Partial response to first generation SSA guides the choice and predict the outcome of second line therapy in acromegaly. Endocrine 78:343–353. https://doi.org/10.1007/s12020-022-03158-w

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chiloiro S, Giampietro A, Mirra F et al (2021) Pegvisomant and pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response. Eur J Endocrinol 184:217–229. https://doi.org/10.1530/EJE-20-0767

Article  CAS  PubMed  Google Scholar 

Gadelha MR, Bronstein MD, Brue T et al (2014) Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol 2:875–884. https://doi.org/10.1016/S2213-8587(14)70169-X

Article  CAS  PubMed